Home › NDC Lookup › RxCUI directory › RxCUI 539817

Solifenacin succinate 5 MG Oral Tablet [Vesicare] — RxCUI 539817

RxNorm drug concept · Semantic branded drug
RxCUI 539817 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI539817
Official nameSolifenacin succinate 5 MG Oral Tablet [Vesicare]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asVESIcare 5 MG Oral Tablet
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)765 prescriptions · 4 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Solifenacin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • In adults, it treats overactive bladder, which means sudden urges, frequent urination, and leaking. A liquid form, VESIcare LS, is for children 2 and older with neurogenic detrusor...
  • Tablets are taken by mouth once a day, with or without food. The liquid is also once daily, followed by water or milk. Follow your prescriber's directions and the label.
  • Dry mouth and constipation are the most common. Blurred vision, dry eyes, and urinary tract infections can also happen. Most are manageable, so tell us if they bother you.
  • Get emergency help for swelling of the face, lips, tongue or throat, or trouble breathing. Call your doctor if you cannot urinate, become very constipated, feel confused, see thing...
📖 Read our full Solifenacin guide →

🕸️ Concept Web — How Solifenacin succinate 5 MG Oral Tablet [Vesicare... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Solifenacin succinate 5 MG Oral Tablet [Vesicare] RxCUI 539817

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Solifenacin 322167
    • Solifenacin succinate 476588
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Vesicare 539812
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Solifenacin Oral Tablet 477371
    • Solifenacin succinate Oral Tablet 2645656
    • Solifenacin Oral Product 1159949
    • Solifenacin Pill 1159950
    • Solifenacin succinate Oral Product 2661426
    • Solifenacin succinate Pill 2662647
    • Solifenacin Oral Tablet [Vesicare] 539814
    • Solifenacin succinate Oral Tablet [Vesicare] 2657087
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Solifenacin succinate 5 MG Oral Tablet SCD · 477367
  • Solifenacin succinate 5 MG SCDC · 477368
  • Solifenacin Oral Tablet SCDF · 477371
  • Solifenacin succinate Oral Tablet SCDFP · 2645656
  • Solifenacin Oral Product SCDG · 1159949
  • Solifenacin Pill SCDG · 1159950
  • Solifenacin succinate Oral Product SCDGP · 2661426
  • Solifenacin succinate Pill SCDGP · 2662647

Brand-Name Concepts

  • Solifenacin succinate 5 MG [Vesicare] SBDC · 539816
  • Solifenacin Oral Tablet [Vesicare] SBDF · 539814
  • Solifenacin succinate Oral Tablet [Vesicare] SBDFP · 2657087
  • Vesicare Oral Product SBDG · 1187116
  • Vesicare Pill SBDG · 1187117
  • Vesicare BN · 539812

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 539817 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
51248-0150-01 30 TABLET, FILM COATED in 1 BOTTLE (51248-150-01) VESIcare Astellas Pharma US, Inc. 2005-01-05
51248-0151-01 30 TABLET, FILM COATED in 1 BOTTLE (51248-151-01) VESIcare Astellas Pharma US, Inc. 2005-01-05
Observed labelers: Astellas Pharma US, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.